318 related articles for article (PubMed ID: 28515111)
21. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
He W; Fang F; Varnum C; Eriksson M; Hall P; Czene K
J Clin Oncol; 2015 Jul; 33(20):2262-9. PubMed ID: 26033800
[TBL] [Abstract][Full Text] [Related]
23. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
24. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
25. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
[TBL] [Abstract][Full Text] [Related]
26. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
27. Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
He W; Smedby KE; Fang F; Olsson H; Margolin S; Hall P; Czene K
J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28423398
[TBL] [Abstract][Full Text] [Related]
28. Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.
Venigalla S; Carmona R; Guttmann DM; Jain V; Freedman GM; Clark AS; Shabason JE
JAMA Oncol; 2018 Oct; 4(10):e181114. PubMed ID: 29800030
[TBL] [Abstract][Full Text] [Related]
29. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
30. Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis.
Zeng E; He W; Sjölander A; Bergqvist J; Fang F; Czene K
J Natl Cancer Inst; 2024 Jun; 116(6):920-928. PubMed ID: 38471102
[TBL] [Abstract][Full Text] [Related]
31. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
[TBL] [Abstract][Full Text] [Related]
32. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.
Zheng D; Thomas J
Breast Cancer Res Treat; 2023 Aug; 201(1):89-104. PubMed ID: 37326766
[TBL] [Abstract][Full Text] [Related]
33. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
34. Mortality impact of less-than-standard therapy in older breast cancer patients.
Yood MU; Owusu C; Buist DS; Geiger AM; Field TS; Thwin SS; Lash TL; Prout MN; Wei F; Quinn VP; Frost FJ; Silliman RA
J Am Coll Surg; 2008 Jan; 206(1):66-75. PubMed ID: 18155570
[TBL] [Abstract][Full Text] [Related]
35. Mental Health Comorbidities and Elevated Risk of Opioid Use in Elderly Breast Cancer Survivors Using Adjuvant Endocrine Treatments.
Desai R; Camacho F; Tan X; LeBaron V; Blackhall L; Balkrishnan R
J Oncol Pract; 2019 Sep; 15(9):e777-e786. PubMed ID: 31322988
[TBL] [Abstract][Full Text] [Related]
36. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women.
Nayyar A; Strassle PD; Iles K; Jameison D; Jadi J; McGuire KP; Gallagher KK
Ann Surg Oncol; 2020 Nov; 27(12):4853-4860. PubMed ID: 32918178
[TBL] [Abstract][Full Text] [Related]
37. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype.
Vaz-Luis I; Lin NU; Keating NL; Barry WT; Lii H; Winer EP; Freedman RA
Breast Cancer Res Treat; 2015 Jun; 151(3):697-707. PubMed ID: 26022349
[TBL] [Abstract][Full Text] [Related]
38. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
39. Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Park C; Park SK; Woo A; Ng BP
Qual Life Res; 2022 May; 31(5):1345-1357. PubMed ID: 35064415
[TBL] [Abstract][Full Text] [Related]
40. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
